GlaxoSmithKline Survives Technical Woes To Win US FDA Panel Nod For Belantamab

Benefits of the BCMA-directed antibody-drug conjugate outweigh its ocular risks in heavily pretreated multiple myeloma patients, Oncologic Drugs Advisory Committee says at the conclusion of a virtual meeting beset by technical problems.

Oncologic Drugs Advisry Committee Meeting has technical difficulties
FDA had to restart the ODAC meeting two hours after it originally began due to technical problems. • Source: Screen shot

GlaxoSmithKline plc overcame ocular toxicity concerns – and a host of technical problems – to score a US Food and Drug Administration panel endorsement for its multiple myeloma drug belantamab mafodotin during a trouble-filled virtual meeting on 14 July.

All of the members of the Oncologic Drugs Advisory Committee who remained at the meeting’s conclusion, more than 2.5 hours...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United States

More from North America